Reduced price! Stugeron 25mg 200 tabl Expand

Stugeron 25mg 200 tabl




Therapeutic indications

More details


tax incl.

14,30€ tax incl.


Stugeron 25mg 200 tabl



Therapeutic indications
• Maintenance therapy for symptoms of labyrinth disorders, including vertigo, dizziness, ringing in the ears (tinitus), nystagmus, nausea and vomiting.
• Prophylaxis of motion sickness.
• Prophylaxis of migraine.
• Maintenance therapy for symptoms of cerebrovascular origin, including dizziness, ringing in the ears (tinitus), vascular headache, antisocial behavior and irritation, memory loss and lack of concentration.
• Maintenance of signs of peripheral circulatory disorders, including Raynaud's syndrome, Acrocyanosis, intermittent claudication, trophic disorders, peptic trophicum and varicosum, paresthesia, nocturnal cramps, cold extremities.

Dosage and method of administration

Cerebral circulation disorders:
1 tablet of 25 mg t.i.d. or 3 x 8 drops (= 3 x 24 mg) daily.
Peripheral vascular disorders:
2.3 tablets of 25 mg t.i.d. or 2-3 x 25 drops (= 2-3 x 75 mg) daily.
Balance Disorders:
1 tablet of 25 mg t.i.d. or 3 x 8 drops (= 3 x 24 mg) daily.
Motion sickness:
- Adult: 1 tablet of 25 mg or 8 drops (= 24 mg) thirty minutes before departure, every six hours should be repeated intake.
- In children: half the adult dose is recommended.
STUGERON should preferably be taken after meals.
The oral suspension should be shaken before use.
The maximum recommended dose of 225 mg per day may (9 tablets) limit. Since the effect of dizziness on STUGERON dose dependent, the dose should be gradually increased.

This is a medicine, no prolonged use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor.

Hypersensitivity to the active substance or to any of the excipients.

Special warnings and precautions for use
Like other antihistamines may STUGERON epigastric problems cause by to take after a meal reduced gastric irritation.
In patients with Parkinson's disease STUGERON should only be administered if the benefits outweigh the potential risk of worsening of this condition.
STUGERON may cause drowsiness, especially at the beginning of treatment. Therefore, caution with concomitant use of alcohol or CNS suppressants.

Interaction with other medicinal products and other forms of interaction
Alcohol / drugs acting on the CNS / tricyclic antidepressants: Concurrent use is the sedative effect of each of these medicines or enhance STUGERON.
Interference with diagnosis: Because the anti-histamine effect STUGERON the normal positive response to the dermal reactiviteitsindicatoren suppression is used to 4 days before the skin tests.

Pregnancy and lactation
Although STUGERON studies in animals have shown no teratogenic effects, they may like all drugs used during pregnancy only if the therapeutic benefits outweigh the potential risks to the fetus.
There are no data on excretion of STUGERON in breast milk: breast feeding should therefore not recommended for women who use STUGERON.

Effects on ability to drive and use machines
Since especially in the early treatment of drowsiness may occur, caution is advised in activities such as driving or using machinery.

Side effects
Somnolence and gastro-intestinal disturbances may occur. These are usually transient and can often be prevented by the dose gradually to build up the optimal dose. In rare cases, headache, dry mouth, weight gain, transspiratie or allergic reactions are possible. Thus, even in very rare cases, lichen planus and lupus-like symptoms reported.
The medical literature was an isolated case of cholestatic jaundice have been reported.
In elderly people cases of aggravation or occurrence of extrapyramidal symptoms described, sometimes associated with depression during prolonged therapy. Treatment should be discontinued in such cases.

Cinnarizine-acute overdoses were reported at doses of 90 to 2250 mg. The most frequently reported signs and symptoms associated with overdose of Cinnarizine include: awareness of changes to stupor and coma, drowsiness, vomiting, extrapyramidal symptoms, and hypotonia. In a small number of attacks occurred in young children. The clinical effects were not severe in most cases, but death was reported after single overdose and overdose of medication including poly Cinnarizine.
There is no specific antidote. For each overdosage symptomatic and supportive treatment is recommended. Within the first hours after ingestion, gastric lavage may be considered. Any activated carbon can be administered.

Delivery form Tablets
Type of product Medicine
Brands Johnson & Johnson

This is a medecine

This is a medecine available without a prescription.. Do not use long without medical advice. Read the instructions carefully. Keep this medicine out of the reach of children. Keep the manual as it contains important information. Ask for advice from your doctor or pharmacist. Consult your doctor if adverse reactions.


  • Fagg